Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials.
Leach
M O
MO
Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee (PTAC), Drug Development Office, Cancer Research UK, London, UK.
Brindle
K M
KM
Evelhoch
J L
JL
Griffiths
J R
JR
Horsman
M R
MR
Jackson
A
A
Jayson
G
G
Judson
I R
IR
Knopp
M V
MV
Maxwell
R J
RJ
McIntyre
D
D
Padhani
A R
AR
Price
P
P
Rathbone
R
R
Rustin
G
G
Tofts
P S
PS
Tozer
G M
GM
Vennart
W
W
Waterton
J C
JC
Williams
S R
SR
Workman
P
P
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D015195:Drug Design; D006801:Humans; D018810:Magnetic Resonance Angiography / Q000379:methods*; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D015203:Reproducibility of Results
D020533:Angiogenesis Inhibitors